Long-term data show the atypical antipsychotic reduced relapse risk by 63%, with 84% of patients with schizophrenia being relapse-free over 6 months.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/fda-oks-lumateperone-caplyta-prevention-schizophrenia-2026a1000die?src=rss
Author :
Publish date : 2026-04-28 13:38:00
Copyright for syndicated content belongs to the linked Source.
